{"id":"amoxicillin-clavulanate-potassium-1gm","safety":{"commonSideEffects":[{"rate":"5-10%","effect":"Diarrhea"},{"rate":"3-5%","effect":"Nausea"},{"rate":"1-3%","effect":"Vomiting"},{"rate":"1-3%","effect":"Rash"},{"rate":"1-3%","effect":"Abdominal pain"},{"rate":"<1%","effect":"Allergic reactions (including anaphylaxis)"}]},"_chembl":{"chemblId":"CHEMBL1003","moleculeType":"Small molecule","molecularWeight":"237.25"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Amoxicillin is a beta-lactam antibiotic that disrupts peptidoglycan cross-linking in bacterial cell walls, leading to cell lysis and death. Clavulanate potassium is a beta-lactamase inhibitor that protects amoxicillin from degradation by bacterial beta-lactamase enzymes, thereby extending amoxicillin's spectrum of activity to include beta-lactamase-producing organisms.","oneSentence":"Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while clavulanate potassium inhibits beta-lactamase enzymes that would otherwise inactivate amoxicillin.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:42:21.598Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Bacterial infections caused by susceptible organisms including otitis media, sinusitis, respiratory tract infections, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections"}]},"trialDetails":[{"nctId":"NCT00343135","phase":"PHASE4","title":"AUGMENTIN 1gm In Skin And Soft Tissue Infection","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2004-12","conditions":"Skin Diseases, Infectious, Infection, Soft Tissue","enrollment":195}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"amoxicillin/clavulanate potassium 1gm","genericName":"amoxicillin/clavulanate potassium 1gm","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Amoxicillin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins, while clavulanate potassium inhibits beta-lactamase enzymes that would otherwise inactivate amoxicillin. Used for Bacterial infections caused by susceptible organisms including otitis media, sinusitis, respiratory tract infections, urinary tract infections, skin and soft tissue infections, and intra-abdominal infections.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}